Clinical trials: Disorder, Mood
Treatment-resistant Depression
A Study to Evaluate the Efficacy, Safety, and Tolerability of Fixed Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression
The purpose of this study is to compare the efficacy and safety of switching treatment-resistant depression (TRD) participants from a prior antidepressant treatment (to which they have not responded) to either intranasal…
- Trial name
- TRANSFORM-1 (NCT02417064)
- Testing
- Esketamine, Duloxetine (Oral Antidepressant), Escitalopram (Oral antidepressant)
- Where
- 90 sites in United States, Belgium and 7 more
- Volunteers
- 346 people
- Sponsor
- Janssen Research & Development, LLC
Depression, Mild Cognitive Impairment
Combination Treatment Study for Memory Impairment and Depression
Patients presenting with depression (DEP) and cognitive impairment (CI), represent a unique, understudied population that is difficult to diagnose, treat and estimate prognosis.
- Trial name
- DEP-CI (NCT01658228)
- Testing
- Donepezil, Citalopram, Venlafaxine
- Where
- 2 sites in United States
- Volunteers
- 86 people
- Sponsor
- New York State Psychiatric Institute
Treatment Resistant Depression
Repetitive Transcranial Magnetic Stimulation for Adolescent Depression: Efficacy, Predictive Biomarkers, and Mechanisms
This study will be an open-label 6-week (30 session) trial of active repetitive transcranial magnetic stimulation (rTMS) using a fixed frequency (10 Hz) but varying stimulation intensities using a 3+3 study design for safety and…
- Trial name
- NCT02611206
- Testing
- Active Repetitive Transcranial Magnetic Stimulation (rTMS): intensity 80% MT, Device: Active Repetitive Transcranial Magnetic Stimulation (rTMS); Stimulation intesity: 100% of MT, Device: Active Repetitive Transcranial Magnetic Stimulation (rTMS); Stimulation intesity: 120% of MT
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- University of Minnesota
Depressive Disorder, Major
A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed Dose Study Evaluating the Efficacy and Safety of Orvepitant in Subjects With Major Depressive Disorder
This is a 6-week, randomised, multicenter, double-blind, placebo controlled, fixed dose parallel group study to assess the efficacy and safety of orvepitant (30 and 60 mg/day) versus placebo in subjects with a diagnosis of a…
- Trial name
- orvepitant MDD (NCT00880399)
- Testing
- orvepitant
- Where
- 20 sites in United States, Canada
- Volunteers
- 328 people
- Sponsor
- GlaxoSmithKline
Depression, Major Depressive Disorder
Relapse-Prevention Study With Levomilnacipran ER (F2695 SR) in Patients With Major Depressive Disorder
The purpose of this study is to evaluate the safety and efficacy of Levomilnacipran ER relative to placebo in the prevention of depression relapse in patients with major depressive disorder (MDD).
- Trial name
- NCT01085812
- Testing
- Levomilnacipran ER
- Where
- 35 sites in United States, Canada
- Volunteers
- 734 people
- Sponsor
- Forest Laboratories
Borderline Personality Disorder, Major Depressive Disorder
Psilocybin in Co-occuring Major Depressive Disorder and Borderline Personality Disorder
The primary objective of the study is to evaluate the safety and efficacy of psilocybin in adults with major depressive disorder (MDD) and borderline personality disorder (BPD).
- Trial name
- NCT05399498
- Testing
- Psilocybin
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of Chicago
Major Depressive Disorder, Generalized Anxiety Disorder
Quetiapine Extended Release (XR) Treatment of Major Depressive Disorder With Comorbid Generalized Anxiety Disorder
The primary objective is to test the hypothesis that quetiapine XR (Extended Release) monotherapy or adjunctive therapy to antidepressant is superior to placebo monotherapy or placebo adjunctive therapy to antidepressant(s) in…
- Trial name
- MDD/GAD (NCT00868374)
- Testing
- Quetiapine XR
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Keming Gao
Major Depressive Disorder
Early Versus Delayed Switch in Medication in Patients With Major Depressive Disorder
This study investigates two different approaches to the change in antidepressant treatment when an initial treatment is not effective: early intervention or delayed intervention. Two hypothesis will be tested: 1.
- Trial name
- NCT00810069
- Testing
- Duloxetine Hydrochloride, Escitalopram
- Where
- 60 sites in Denmark, France and 9 more
- Volunteers
- 840 people
- Sponsor
- Eli Lilly and Company
Treatment-resistant Depression
Efficacy of Repeated Ketamine Infusions for Treatment-resistant Depression
About one-third of depressed patients will not get better after multiple antidepressant treatments. This situation put a high burden on patients with depression due to worsening quality of life and increasing health care costs.
- Trial name
- NCT02360280
- Testing
- ketamine, midazolam
- Where
- United States
- Volunteers
- 62 people
- Sponsor
- VA Office of Research and Development
Bipolar Disorder
Bipolar Transcranial Alternating Current Stimulation (tACS)
The purpose of this clinical trial is to measure the safety and effectiveness of a non-invasive brain stimulation device called Transcranial Alternating Current Stimulation (tACS) in participants with bipolar disorder (BD).
- Trial name
- NCT05480124
- Testing
- tACS brain stimulation treatment
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- University of Michigan
Major Depressive Disorder, Dysthymic Disorder
Antidepressant Response in the Treatment of Depressive Symptoms and Frailty Characteristics in Older Adults
The goal of this open-administration treatment study of citalopram (or duloxetine) is to evaluate the effect of antidepressant medication on treating the syndrome of "frailty" in older adults with depressive symptoms.
- Conditions
- Major Depressive Disorder, Dysthymic Disorder, Depressive Disorder, NOS
- Trial name
- NCT01973283
- Testing
- Antidepressant Medication
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- New York State Psychiatric Institute
Major Depressive Disorder, Insomnia
Time to Remission of Depressive Symptoms With Combined SSRI and Ramelteon
Hypothesis I: Patients in the SSRI + ramelteon treatment group will achieve remission (defined as an IDS-C30 score of 11 or less) more quickly than those in the SSRI + placebo group.
- Trial name
- TAKEDA (NCT00642694)
- Testing
- Escitalopram, Ramelteon
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- University of Texas Southwestern Medical Center
Major Depressive Disorder
Study of the Safety and Efficacy of OPC-34712 as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder
Primary: To compare the efficacy of OPC-34712 to placebo as adjunctive treatment to an assigned open-label marketed antidepressant treatment (ADT)in patients who demonstrate an incomplete response to a prospective eight week…
- Trial name
- NCT00797966
- Testing
- OPC-34712, ADT
- Where
- 50 sites in United States
- Volunteers
- 850 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Major Depressive Disorder
A Study to Evaluate the Efficacy of SAGE-217 in the Treatment of Adult Participants With Major Depressive Disorder
This study is a phase 3, multicenter, double-blind, randomized, placebo-controlled study evaluating the efficacy of SAGE-217 in the treatment of adult participants with major depressive disorder (MDD).
- Trial name
- NCT03672175
- Testing
- SAGE-217
- Where
- 53 sites in United States
- Volunteers
- 581 people
- Sponsor
- Biogen
Major Depressive Disorder
Social Reward and Its Effect on Brain Functions in Psychotherapies for Mid- and Late-Life Depression
Abnormalities in the Positive Valence System (PVS) are associated with depressive symptoms and reduced behavioral activation in mid- and late-life.
- Trial name
- NCT04487730
- Testing
- "Engage & Connect" Psychotherapy, Symptom Review and Psychoeducation (SRP)
- Where
- United States
- Volunteers
- 64 people
- Sponsor
- Weill Medical College of Cornell University
Bipolar Disorder
A Randomized Controlled Trial of Cognitive Remediation and D-cycloserine for Individuals With Bipolar Disorder
Individuals with bipolar suffer from problems in basic cognitive skills such as memory and concentration. Unfortunately, there are no current treatments that have been shown to improve cognitive skills among individuals with…
- Trial name
- DCS (NCT01934972)
- Testing
- CR + DCS (D-cycloserine)
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Arizona
Major Depression, End Stage Renal Disease
Bupropion for Depression in ESRD Patients on Hemodialysis
The proposed study will evaluate the response and remission rates for major depressive disorder (MDD) in end-stage renal disease (ESRD) patients undergoing maintenance hemodialysis (HD) treated with bupropion or fluoxetine for 12…
- Trial name
- NCT02238977
- Testing
- Fluoxetine, Bupropion
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- University of Arkansas
Major Depressive Disorder, Healthy Controls
Effects of Treatment on Decision-making in Major Depression
In this trial, fifty participants with current major depressive disorder who are not receiving an antidepressant medication and fifty healthy controls will complete questionnaires and computerized tasks to assess their…
- Trial name
- NCT01916824
- Testing
- Any FDA Approved Antidepressant
- Where
- United States
- Volunteers
- 53 people, healthy volunteers welcome
- Sponsor
- Emory University
Major Depressive Disorder, Hepatitis C, Chronic
Efficacy and Safety of Escitalopram for Prevention of Depression Induced by Peg-Interferon in Hepatitis C Patients
The purpose of this study is to determine whether the use of an antidepressant (escitalopram) can prevent depressive episodes that appear during the treatment with peg-interferon and ribavirin in patients with chronic hepatitis C.
- Trial name
- NCT00166296
- Testing
- Escitalopram
- Where
- 15 sites in Spain
- Volunteers
- 133 people
- Sponsor
- Germans Trias i Pujol Hospital
Major Depressive Disorder
A Study of Brexpiprazole in Patients With Major Depressive Disorder
The purpose of this 14 week, randomized, double-blind, placebo controlled study is to assess the safety and efficacy of brexipiprazole to placebo as adjunctive treatment to an assigned open-label marketed antidepressant therapy…
- Trial name
- NCT03697603
- Testing
- Brexpiprazole
- Where
- Japan
- Volunteers
- 740 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.